Tech Company Financing Transactions
Platelet Biogenesis Funding Round
On 9/10/2019, Platelet Biogenesis landed $26 million in Series A funding from Qiming Ventures, Ziff Capital Partners and eCoast Angels.
Transaction Overview
Company Name
Announced On
9/10/2019
Transaction Type
Venture Equity
Amount
$26,000,000
Round
Series A
Investors
Qiming Ventures (Lead Investor) (Mark McDade)
Ziff Capital Partners (Lead Investor)
Proceeds Purpose
PBG will use the funds from the Series A-1 round to accelerate the development of its donor-independent platelet manufacturing capabilities and advance its proof of concept work around platelet-based therapeutics.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
325 Vassar St. 2A
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Overview
Platelet BioGenesis is a Harvard University spinout that is making human platelets from stem cells. We have developed and patented a microfluidic bioreactor, and shown that functional platelets can be generated from human pluripotent stem cell cultures.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Sam Rasty
Chief Operating Officer
Sven Karlsson
Chief Scientific Officer
Jonathan Thon
Browse more venture capital transactions:
Prev: 9/9/2019: FieldIn venture capital transaction
Next: 9/10/2019: SGI-DNA venture capital transaction
Share this article
News on VC Transactions
We do our best to record tech company VC transactions. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs